Omnio raises €2.9M to push wound biologic toward trials

What's the deal? Umeå-based biotech OmnioDealroom has a profile for this one. Try Dealroom → has raised €2.9 million in an oversubscribed early VC round from existing investors and shareholders. The money will move its plasminogen-based therapy for hard-to-heal chronic wounds closer to clinical trials, with patient studies planned for 2027.

Why now? The round follows a €4.3 million financing completed in spring 2025. Omnio has established its master cell bank and is scaling up manufacturing for a GMP batch, which will feed the toxicology studies required before it can apply to start clinical trials.

What's the endgame? The clinical program will begin with a Phase I/IIa study of safety and early efficacy in patients with diabetic foot ulcers (DFU), the company's lead indication. Omnio plans to open its next financing round in Q1 2027 to fund development through first efficacy data.

Why it matters: More than half a billion people worldwide live with diabetes, and up to one-third will develop a foot ulcer in their lifetime. These wounds can turn chronic, limiting mobility and risking amputation, and advanced-stage DFU costs healthcare systems an estimated €50,000 per wound episode.

The therapy is based on research by Tor Ny, professor emeritus of medical biochemistry at Umeå University and the company's head of R&D. Omnio sees further potential in venous leg ulcers, burns, tympanic membrane perforations, infection, and periodontitis.

The signal: "The wound healing market is mostly a medical devices market, but nothing has really moved the needle in hard-to-heal wounds," says chief executive officer Felipe Velasquez. Omnio is betting a biologic that targets "the root cause of why these wounds stay open" can do what devices have not.

Read more: nordiclifescience.org

Image credit: Generated with Gemini